Related Experiment Video
Updated: Dec 6, 2025
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Atypical teratoid rhabdoid tumor: molecular insights and translation to novel therapeutics
Cody L Nesvick1, Lucie Lafay-Cousin2, Aditya Raghunathan3
1Department of Neurological Surgery, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Introduction:
Atypical teratoid rhabdoid tumor (ATRT) is a rare, often lethal brain tumor of childhood characterized by a complex epigenetic landscape amongst a simple genetic background. Recent molecular studies have defined key biologic events that contribute to tumorigenesis and molecular subtypes of ATRT.
Methods:
Seminal studies on ATRT are reviewed with an emphasis on molecular pathogenesis and its relevance to novel therapeutics.
Results:
In this review, we summarize the key clinicopathologic and molecular features of ATRT, completed and ongoing clinical trials and outline the translational potential of novel insights into the molecular pathogenesis of this tumor.
Conclusions:
SMARCB1 loss is the key genetic event in ATRT pathogenesis that leads to widespread epigenetic dysregulation and loss of lineage-specific enhancers. Current work is defining subtype-specific treatments that target underlying molecular derangements that drive tumorigenesis.
Insights
Atypical teratoid rhabdoid tumors (ATRT) are rare childhood brain cancers. SMARCB1 loss drives ATRT, leading to epigenetic changes, and new treatments target these molecular drivers.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Epigenetics
Background:
- Atypical teratoid rhabdoid tumor (ATRT) is a rare, aggressive pediatric brain tumor.
- Characterized by a complex epigenetic landscape and simple genetic background.
- Recent research has identified key molecular events and subtypes driving ATRT.
Purpose of the Study:
- Review seminal studies on ATRT.
- Emphasize molecular pathogenesis and its therapeutic relevance.
- Summarize clinicopathologic features, trials, and translational potential.
Main Methods:
- Literature review of key ATRT studies.
- Focus on molecular pathogenesis and therapeutic strategies.
- Analysis of clinical trials and translational research.
Main Results:
- SMARCB1 loss is the primary genetic driver of ATRT.
- This loss causes widespread epigenetic dysregulation and enhancer abnormalities.
- Molecular subtypes of ATRT are being defined.
Conclusions:
- SMARCB1 loss initiates ATRT through epigenetic alterations.
- Ongoing research focuses on subtype-specific treatments targeting molecular drivers.
- Translational potential exists for novel therapeutic strategies based on molecular insights.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...